News

bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

This feature covers the latest fundraise and appointments to the board.

Funding raised to accelerate and expand cell therapy pipeline.

bit.bio adds $100M+ to its coffers and some impressive names to its board of directors.

Three world leaders in science and entrepreneurship appointed to bit.bio's Board of Directors.

Dr Davide Danovi talks to The Academy of Medical Sciences as a FLIER participant in cross-sector leadership programme.

This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.